Premium
A Carlyle Group-backed pharmaceuticals platform has agreed to acquire a bulk drugs business, the second active pharmaceuticals ingredients (API) bet for the private equity firm in India, three people told VCCircle. Carlyle-backed Viyash Life Sciences Pvt Ltd will buy Hyderabad-based Symed Labs Pvt Ltd for Rs 1,600 crore ($215 ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
